Sumitomo Chemi. Q1 FY27 Results (NSE: SUMICHEM)
Signal: Margin expansion
The read
Revenue barely grew (+0.6% YoY) but margins expanded sharply: EBITDA margin +197bps to 26.4% on input cost relief. PAT +20.4% was amplified by a ₹269M insurance claim (exceptional item); core PAT (ex-exceptional) rose only ~5.3%. The Q1 seasonal sequential jump is normal for agrochemicals. Overall, a mixed quarter: margin improvement is positive, but top-line stagnation and reliance on exceptional income for double-digit PAT growth warrant caution.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,063.35 Cr | +0.6% | +55.5% |
| EBIT | ₹280.57 Cr | +8.8% | |
| Net profit | ₹214.51 Cr | +20.4% | |
| EPS | ₹4.3 | +20.4% | |
| EBIT margin | 26.4% |
P&L walk
Margin expansion was the main story: EBITDA margin rose 197bps YoY to 26.4%, driven by lower raw material costs (COGS % down 112bps) and slight operating expense control, while revenue barely grew (+0.6%). PAT was further boosted by a ₹269M insurance claim exceptional income.
Key positives
- EBITDA margin expanded 197bps YoY to 26.4%, driven by lower raw material costs (COGS % down 112bps).
- PAT grew 20.4% YoY to ₹2,145M, with help from a ₹269M insurance claim exceptional income.
- Balance sheet remains debt-light (finance cost only ₹20M, D/E 0.02 from fundamentals).
Key concerns
- Revenue growth almost flat (+0.6% YoY), indicating volume stagnation or pricing pressure.
- Core operating profit (ex-exceptional) grew only ~5.3%, well below margin expansion potential.
- Glyphosate regulatory overhang persists; notification stayed by court but uncertainty remains.
Research and educational content only. Not investment advice.